![]() ![]() “Our aim with this novel, single-administration gene therapy is to use our development expertise and deep heritage in vision care to help improve patient outcomes by intervening early, halting the progression to blindness, and preserving more years of sight. LinkedIn Email Finder Find emails from LinkedIn. List, MD, PhD, global therapeutic area head, Cardiovascular and Metabolism, Janssen Research & Development, in the press release. Hemera Biosciences email format Hemera emails. STATUS: Not Recruiting participants needed: 25 sponsor: Hemera Biosciences Condition, Wet Age Related Macular Degeneration Treatment, Intravitreal anti-VEGF. To connect with Hemera Biosciences LLC employee register on SignalHire. The annual revenue of Hemera Biosciences LLC varies between 5.0M and 25M. The number of employees ranges from 1 to 25. AAVCAGsCD59, also denoted HMR59, is an intravitreally injected AAV vector developed by Hemera Biosciences that induces the formation of CD59, thereby preventing the binding of C9 required for the formation of a complete MAC. 2, 2020 /prnewswire/ - janssen pharmaceuticals, inc., one of the janssen pharmaceutical companies of johnson & johnson, today announced the acquisition of rights to hemera. Its headquarters is located at Newton, Massachusetts, USA. Regulators of the complement cascade are emerging targets for investigational compounds. ![]() “Geographic atrophy is a devastating form of AMD that impacts the ability to accomplish everyday tasks, such as reading, driving, cooking, or even seeing faces,” said James F. The position of the Founder & CEO is occupied by Adam Rogers. 2, 2020 that it has acquired US-based biotechnology company Hemera Biosciences’ investigational gene therapy, HMR59, for the preservation of vision in patients with geographic atrophy, a form of age-related macular degeneration (AMD).Īccording to a Janssen press release, the gene therapy works to increase the ability of retina cells to make a soluble form of CD59, a protein that shields the retina from damage, to prevent additional damage to the retina and to preserve vision. The HEMERA BIOSCIENCES is under the trademark classification: Pharmaceutical Products The HEMERA BIOSCIENCES trademark covers Pharmaceuticals for the treatment of macular degeneration and other. This trademark was filed to USPTO on Saturday, March 12, 2016. As physicians and scientists, we have been frustrated by our inability to provide treatment for our patients with macular degeneration. Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced on Dec. HEMERA BIOSCIENCES is a trademark and brand of Hemera Biosciences, Inc., Waltham, MA. Founded in 2010 Private Company 'Hemera Biosciences was founded with the sole mission of preserving vision using gene therapy in our patients with age-related macular degeneration (AMD). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |